A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-19

Study Completion Date

2026-11-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

NCT00580242

Myelodysplasia

COMPLETED PHASE1

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

NCT01731886

Multiple Myeloma

COMPLETED PHASE4

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

NCT01054196

Multiple Myeloma

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

NCT01050790

Multiple Myeloma

COMPLETED NA

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

NCT06863584

Solitary Plasmacytoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasmacytoma Plasmacytoma of Bone Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Plasmacytoma

Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas

Group Type EXPERIMENTAL

CC-486

Intervention Type DRUG

Participants will be treated with CC-486 and lenalidomide for 6 cycles

Lenalidomide

Intervention Type DRUG

Participants will be treated with CC-486 and lenalidomide for 6 cycles

Radiation Therapy

Intervention Type RADIATION

Radiation therapy will be initiated to the plasmacytoma after cycle 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CC-486

Participants will be treated with CC-486 and lenalidomide for 6 cycles

Intervention Type DRUG

Lenalidomide

Participants will be treated with CC-486 and lenalidomide for 6 cycles

Intervention Type DRUG

Radiation Therapy

Radiation therapy will be initiated to the plasmacytoma after cycle 2

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cohort 1: Must meet all the following 3 criteria:

* Histologically confirmed newly diagnosed or recurrent solitary plasmacytoma/lytic lesion (recurrent solitary plasmacytomas will be considered based on treating physician discretion for cases where they clinically plan to treat with RT alone) - Minimal marrow involvement (Detectable clonal bone marrow plasma cells by multicolor flow cytometry and \</= 10% clonal plasma cells in a bone marrow biopsy by immunohistochemistry, morphology, or flow cytometry)
* Secretory M protein \< 3 g/dL

Cohort 2: Must meet all the following criteria:

* Relapsed multiple myeloma with plasmacytomas/lytic lesion appropriate for RT on imaging
* Relapsed (reappearance of M-spike/serum FLC) or progressive myeloma defined by a 25% increase from nadir in M-spike or involved serum FLB on 2 separate measurements; or with bone marrow involvement by clonal plasma cells detectable by IHC or flow cytometry.
* Any prior number of therapies is permitted, including prior radiation therapy
* Allogeneic transplant patients are permitted

All Cohorts:

* Age \>/= 18 years
* Surgical resection of plasmacytoma or stabilization surgery is permitted if necessary based on physician judgement
* ECOG performance status of 0-1
* Anticipated lifespan greater than 3 months
* Able and willing to give valid written informed consent
* Creatinine clearance \>/=30ml/min by Cockroft-Gault method. See section below, "Dosing Regimen", regarding lenalidomide dose adjustment for calculated creatinine clearance \>/= 30ml/min and \<60ml/min
* Serum bilirubin levels \</= 1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis of Gilbert's syndrome
* AST (SGOT) and ALT (SGPT) \</= 2.5 x ULN
* Women of childbearing potential should be advised to avoid becoming pregnant and must adhere to the scheduled pregnancy testing a required in the Revlimid REMS program. They must be agreeable to use acceptable methods of birth control throughout the study and for at least 6 months after the last dose:

Recommendation is for 2 effective contraceptive methods during the study and for at least 6 months after the last dose. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptive, intrauterine devices, and tubal ligation.

* Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of investigational product (IP). Men should be advised to not father a child while receiving treatment with azacitidine. Male patients with female partners who are of childbearing potential: Recommendation is for the patient and partner use at least 2 effective contraceptive methods, as described above, during the study and for 3 months following the last dose of study drug.

Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP.

* Willing to be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program.
* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use physician's choice of anticoagulation).
* Able to swallow oral medication
* Hematologic criteria: Hemoglobin \>/= 9 g/dL, platelets \>/= 50,000 and ANC \>/= 1

Exclusion Criteria

* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking azacitidine).
* Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
* History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity
* Abnormal coagulation parameters without any known etiology (PTT \> 45 seconds, and/or INR \> 1.5). Patients currently on therapeutic anti-coagulation treatment are exempt from these parameters.
* Significant active cardiac disease within the previous 6 months including:

NYHA class 4 CHF Unstable angina Myocardial infarction

* known or suspected hypersensitivity to azacitidine or mannitol
* Known hypersensitivity to thalidomide or lenalidomide
* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
* Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) as determined by a positive Polymerase Chain Reaction (PCR) will be excluded. Patients who are seropositive because of HBV vaccine are eligible. Seropositive status-antibody positive patients with negative PCR on two occasions will be eligible
* Concurrent systemic chemotherapy with drugs other than CC-486 and lenalidomide.
* Patients on tacrolimus therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No